The prostate cancer diagnostics market size was estimated at USD 9.72 billion in 2025 and is projected to attain around USD 18 billion by 2035, growing at a notable CAGR of 6.36 % from 2026 to 2035.
Preventive testing is one of modern medicine’s most powerful tools. Essential medical tests are not designed to search for illness in healthy people; they are designed to protect health before disease ...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025.
Major research paper underpins the calls of leading cardiac charity, which first pioneered & funded an internationally ...
Major research paper underpins the calls of leading cardiac charity, which first pioneered & funded an internationally acclaimed screening programme 30 years ago New study publicly calls into ...
MEN over 40 in Inverclyde have another opportunity to get a free prostate cancer test as McGill’s Buses continue their ...
Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen ...
At her office in the Ohio Valley Health Center, Ann Quillen pointed to a painting of North Fourth Street by local artist Dave Barnhouse. She noted the center’s original location on North Fourth Street ...
At her office in the Ohio Valley Health Center, Ann Quillen pointed to a painting of North Fourth Street by local artist Dave Barnhouse. She noted the center’s original location on North Fourth Street ...
More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests "The breadth of data at ASCO GU ...
Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results